Меню
Идёт набор NCT04378439

Appalachian Partnership to Reduce Disparities (Aim 2)

Без фазы С лечением HIV/AIDS STI HCV

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Peer Navigation, mHealth.
Кому может быть актуально
Состояния в реестре: HIV/AIDS, STI, HCV. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Harnessing the Power of Peer Navigation and mHealth to Reduce Health Disparities in Appalachia

Обзор

By combining two strategies (i.e., peer navigation and mHealth) into a complete, culturally compatible, bilingual intervention to increase the use of needed HIV, STI, and HCV prevention and care services among racially/ethnically diverse GBMSM and transgender women in rural Appalachia. Study Investigators anticipate that participants in the intervention group, relative to counterparts in the delayed-intervention group, will demonstrate increased HIV, STI, and HCV testing.

Подробное описание

This CBPR study will advance prevention science and practice through testing an innovative intervention to promote and support the use of needed HIV, STI, and HCV prevention and care services among GBMSM and transgender women; and developing priorities and recommendations to improve their health that will be disseminated to inform public health practice, research, and policy. By integrating peer navigation and mHealth strategies, the proposed study provides a unique opportunity to improve health among vulnerable, hidden, and neglected populations living in rural Appalachia. Findings from this research may inform strategies and approaches to address other health disparities in other rural populations.

Вмешательства

  • Поведенческое Peer Navigation
    First, as health advisors, community health leaders will raise awareness of HIV, STIs, and HCV and local prevention and care services and help social network members access services. Thus, the community health leader will describe to the process for HCV testing, and how providers are required to maintain confidentiality. As opinion leaders, community health leaders will reframe health-compromising and bolster health-promoting norms and expectations about testing and use of other prevention and c
  • Поведенческое mHealth
    In addition to in-person individual and group activities, community health leaders will use mHealth platforms preferred by each social network member (i.e., Facebook , Instagram, testing, and/or GPS-based mobile apps) to communicate with them during the intervention. They will use social media to plan activities and to support use of needed prevention and care services. For example, when planning a group activity (described above), the community health leader will use social media to remind soci

Первичные конечные точки

  • Number of participants who have Human Immunodeficiency Virus (HIV) testing [Срок оценки: baseline]
  • Number of participants who have Sexually Transmitted Infection (STI) testing [Срок оценки: baseline]
  • Number of participants who have Hepatitis C Virus (HCV) testing [Срок оценки: baseline]
  • Number of participants who have HIV testing [Срок оценки: immediate post-intervention (12 months post-baseline)]
  • Number of participants who have STI testing [Срок оценки: immediate post-intervention (12 months post-baseline)]
  • Number of participants who have HCV testing [Срок оценки: immediate post-intervention (12 months post-baseline)]
  • Number of participants who have HIV testing [Срок оценки: 12-month follow-up (24 months post-baseline)]
  • Number of participants who have STI testing [Срок оценки: 12-month follow-up (24 months post-baseline)]
  • Number of participants who have HCV testing [Срок оценки: 12-month follow-up (24 months post-baseline)]
Вторичные конечные точки (6)
  • Number of participants who use prevention--Pre-exposure prophylaxis (PrEP) [Срок оценки: baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).]
  • Number of participants who use prevention--syringe services [Срок оценки: baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).]
  • Number of participants who use HIV care services [Срок оценки: baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).]
  • Number of participants who use STI treatment services [Срок оценки: baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).]
  • Number of participants who use HCV treatment services [Срок оценки: baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).]
  • Number of participants who use gender-affirming care services [Срок оценки: baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).]

Критерии участия

Критерии включения

  • reside in one of the rural Appalachian catchment countiesreside in one of the rural Appalachian catchment counties
  • be ≥18 years of age
  • report being assigned male sex at birth and having had sex with at least 1 man in past 12 months
  • provide informed consent

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Простое слепое
Основная цель
Профилактика

Центры проведения

США · 1 центр
  • Wake Forest University Health Sciences — Winston-Salem

Идентификаторы

NCT: NCT04378439 · IRB00065116 · R01NR019512

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗